LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

37.23 0.49

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

35.79

Max

37.94

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
EPS	-0.5
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+40.12% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	705M 6.3B
Iepriekšējā atvēršanas cena	36.74
Iepriekšējā slēgšanas cena	37.23

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. marts 23:01 UTC

Peļņas

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

2026. g. 5. marts 21:54 UTC

Peļņas

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

2026. g. 5. marts 21:35 UTC

Galvenie tirgus virzītāji

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

2026. g. 6. marts 00:00 UTC

Galvenie ziņu notikumi

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

2026. g. 5. marts 23:46 UTC

Tirgus saruna

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

2026. g. 5. marts 23:33 UTC

Tirgus saruna

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026. g. 5. marts 23:27 UTC

Tirgus saruna

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

2026. g. 5. marts 22:54 UTC

Tirgus saruna

Peļņas

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

2026. g. 5. marts 22:50 UTC

Tirgus saruna

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

2026. g. 5. marts 22:48 UTC

Peļņas

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026. g. 5. marts 22:46 UTC

Peļņas

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

2026. g. 5. marts 22:44 UTC

Peļņas

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. marts 21:35 UTC

Peļņas

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026. g. 5. marts 21:32 UTC

Peļņas

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026. g. 5. marts 21:26 UTC

Peļņas

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

2026. g. 5. marts 21:24 UTC

Peļņas

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

2026. g. 5. marts 21:23 UTC

Peļņas

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

2026. g. 5. marts 21:22 UTC

Peļņas

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026. g. 5. marts 21:21 UTC

Peļņas

Costco February Digitally-Enabled Sales Rose 21.8% >COST

2026. g. 5. marts 21:21 UTC

Peļņas

Costco Total Co Comparable Sales for February Rose 7.9% >COST

2026. g. 5. marts 21:20 UTC

Peļņas

Costco February Net Sales Were $21.69 B >COST

2026. g. 5. marts 21:20 UTC

Peļņas

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026. g. 5. marts 21:20 UTC

Peļņas

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026. g. 5. marts 21:19 UTC

Peļņas

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

2026. g. 5. marts 21:18 UTC

Peļņas

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

2026. g. 5. marts 21:18 UTC

Peļņas

Costco 2Q Same-Store Sales Up 7.4% >COST

2026. g. 5. marts 21:15 UTC

Peļņas

Costco 2Q EPS $4.58 >COST

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

40.12% augšup

Prognoze 12 mēnešiem

Vidējais 52.18 USD 40.12%

Augstākais 67 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.